CureVac (NASDAQ:CVAC) Sees Large Volume Increase

Shares of CureVac (NASDAQ:CVAC) saw unusually-high trading volume on Wednesday . Approximately 290,327 shares traded hands during mid-day trading, a decline of 63% from the previous session’s volume of 792,572 shares.The stock last traded at $3.66 and had previously closed at $3.29.

Analysts Set New Price Targets

CVAC has been the topic of several research analyst reports. Guggenheim reissued a “neutral” rating on shares of CureVac in a research note on Friday, April 5th. Leerink Partnrs downgraded shares of CureVac from an “outperform” rating to a “market perform” rating in a research report on Thursday, April 25th. Finally, SVB Leerink lowered shares of CureVac from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $12.00 to $4.00 in a research note on Thursday, April 25th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $8.33.

CureVac Stock Up 1.5 %

The company has a debt-to-equity ratio of 0.07, a current ratio of 2.57 and a quick ratio of 2.43. The business has a 50-day moving average of $2.95 and a 200 day moving average of $3.82.

CureVac (NASDAQ:CVAC) last posted its quarterly earnings data on Wednesday, April 24th. The company reported ($0.42) EPS for the quarter. CureVac had a negative net margin of 483.81% and a negative return on equity of 41.85%. The firm had revenue of $24.30 million during the quarter. Equities analysts expect that CureVac will post -0.82 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of CVAC. Ballentine Partners LLC purchased a new position in shares of CureVac in the 1st quarter worth about $38,000. Vontobel Holding Ltd. bought a new position in shares of CureVac during the 4th quarter valued at approximately $45,000. Optiver Holding B.V. increased its stake in shares of CureVac by 2,407.0% during the 3rd quarter. Optiver Holding B.V. now owns 6,844 shares of the company’s stock worth $47,000 after purchasing an additional 6,571 shares during the last quarter. Vanguard Personalized Indexing Management LLC bought a new stake in shares of CureVac in the 4th quarter worth approximately $68,000. Finally, International Assets Investment Management LLC bought a new stake in shares of CureVac in the 4th quarter worth approximately $71,000. Institutional investors own 17.26% of the company’s stock.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.